Trial reportJournal of immunotherapy (Hagerstown, Md. : 1997)
Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study.
Trial report in Journal of immunotherapy (Hagerstown, Md. : 1997). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis.Gynecologic oncology · 2022Pooled it
- Identification of angiogenesis-related genes signature for predicting survival and its regulatory network in glioblastoma.Cancer medicine · 2023Article
- Epithelial Ovarian Cancer: Providing Evidence of Predisposition Genes.International journal of environmental research and public health · 2022Review
- The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Review
- Sperm protein 17 targeting for epithelialovarian cancer treatment in the eraof modern immunoengineering.Molecular therapy oncolytics · 2021Review
- Chimeric Antigen Receptor Design and Efficacy in Ovarian Cancer Treatment.International journal of molecular sciences · 2021Review
- Cell therapies in ovarian cancer.Therapeutic advances in medical oncology · 2021Review
- Immunotherapy for Gynecologic Cancer: Current Applications and Future Directions.Clinical obstetrics and gynecology · 2020Review
- Dendritic Cells Loaded with Heat Shock-Conditioned Ovarian Epithelial Carcinoma Cell Lysates Elicit T Cell-Dependent Antitumor Immune ResponsesJournal of immunology research · 2019Article
- A dynamic transcriptomic atlas of cytokine-induced killer cells.The Journal of biological chemistry · 2018Article
- Surgical immune interventions for solid malignancies.American journal of surgery · 2016Review
- Cellular therapy in combination with cytokines improves survival in a xenograft mouse model of ovarian cancer.Molecular and cellular biochemistry · 2015Article
- Targeted immune therapy of ovarian cancer.Cancer metastasis reviews · 2015Review
- Immunotherapy for ovarian cancer.Current treatment options in oncology · 2015Review
- Tumor infiltrating lymphocytes in ovarian cancer.Cancer biology & therapy · 2015Review
- Comparative study of various subpopulations of cytotoxic cells in blood and ascites from patients with ovarian carcinoma.Contemporary oncology (Poznan, Poland) · 2015Article
- Adoptive T cell immunotherapy for cancer.Rambam Maimonides medical journal · 2015Review
- Past, present and future targets for immunotherapy in ovarian cancer.Immunotherapy · 2014Review
- Proceedings of the Annual Symposium & Plenary Session on Regenerative Medicine (PASRM).Journal of stem cells & regenerative medicine · 2012Article
- Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1.OncoimmunologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
The objective was to evaluate the toxicity and feasibility of intraperitoneal infusion of tumor-specific cytotoxic T lymphocytes (CTL) as therapy for recurrent ovarian cancer, and to determine if repetitive cycles of CTL generation and infusion measurably increases the host's ovarian cancer immune response. In this study, 7 subjects with recurrent ovarian cancer confined to the peritoneal cavity underwent up to 4 cycles, each cycle beginning with a leukapheresis for collection of precursor lymphocytes, which were stimulated in vitro with mucin 1, a tumor-specific antigen found commonly in ovarian cancer cells. The resulting new CTL for each cycle were reintroduced into the host by intraperitoneal infusion. Immunologic parameters (killer cells, cytokine production, memory T lymphocytes, and natural killer cells) were studied. Toxicity, CA-125, and survival data were also evaluated. The tumor marker CA-125 was nonstatistically significantly reduced after the first month of immunotherapy. However, after that it rose. Killer cells, cytokine production, and memory T lymphocytes increased after the first cycle of stimulation, but plateaued or reduced thereafter. The percent of natural killer cells inversely correlated with other immune parameters. Median survival was 11.5 months. One subject is free of disease since December, 2000. Multiple cycles, beyond 1 cycle, of T-cell stimulation followed by adoptive T-cell infusion, may not enhance the in vivo immune response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.